^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Krazati (adagrasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Excerpt:
...Histologically confirmed diagnosis of a pancreatic cancer with KRAS G12C mutation....
Trial ID:
Source:
Title:
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Published date:
04/26/2023
Excerpt:
Among 57 patients with measurable disease at baseline, objective responses were observed in 20 (35.1%) patients (all partial responses), including 7/21 (33.3%) responses in pancreatic and 5/12 (41.7%) in biliary tract cancers....Adagrasib demonstrates encouraging clinical activity and is well tolerated in this rare cohort of pretreated patients with KRASG12C-mutated solid tumors.
DOI:
10.1200/JCO.23.00434
Trial ID:
Source:
Title:
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
Published date:
10/25/2020
Excerpt:
17% (3/18) of evaluable CRC patients had a confirmed objective response...Disease control was observed in 94% (17/18) of patients...Six patients in the other solid tumor cohort were evaluable for clinical activity. Confirmed partial responses (PRs) were observed in a patient with endometrial cancer and a patient with pancreatic cancer (n=1/1 each); unconfirmed PRs were observed in patients with ovarian cancer and CCA (n=1/1 each).
Trial ID:
